US11053214 — Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Method of Use · Assigned to Colucid Pharmaceuticals Inc · Expires 2037-12-05 · 12y remaining
What this patent protects
This patent protects new forms of the hemisuccinate salt of a specific compound, useful in pharmaceutical compositions for treating and preventing migraine headaches.
USPTO Abstract
The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1719 |
— | lasmiditan-succinate |
U-1719 |
— | lasmiditan-succinate |
U-1719 |
— | lasmiditan-succinate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.